ANGPTL4 oligonucleotides affecting the regulation of fatty acid metabolism

Modified antisense oligonucleotides targeting ANGPTL4 mRNA provide a highly effective solution to reduce ANGPTL4 levels, addressing lipid imbalances and associated diseases by achieving up to 100% knockdown, thereby treating cardiometabolic diseases and cancers.

JP7577654B2Active Publication Date: 2024-11-05LIPIGON PHARMA
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2021526428
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-11-13
Filing Date
2019-11-13
Publication Date
2024-11-05
Estimated Expiration
2039-11-13

AI Technical Summary

Technical Problem

Current treatments for cardiometabolic diseases, such as hypertriglyceridemia and cardiovascular diseases, are inadequate in effectively reducing ANGPTL4 levels, which are associated with lipid imbalances and increased risk of these conditions, and existing antisense oligonucleotides are not highly efficient in inhibiting ANGPTL4 expression.

Method used

Development of modified antisense oligonucleotides, including locked nucleic acids (LNA) and 2'fluoro modified nucleotides, that specifically target and inhibit ANGPTL4 mRNA and pre-mRNA expression, achieving significant knockdown of ANGPTL4 activity at nanomolar or micromolar concentrations.

Benefits of technology

The modified antisense oligonucleotides effectively reduce ANGPTL4 expression by up to 100%, providing a therapeutic approach for treating cardiometabolic diseases, obesity, diabetes, and various cancers by targeting lipid metabolism and ANGPTL4 imbalance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577654000018
    Figure 0007577654000018
  • Figure 0007577654000019
    Figure 0007577654000019
  • Figure 0007577654000020
    Figure 0007577654000020
Patent Text Reader

Abstract

The present invention relates to an ANGPTL4 inhibitor consisting of an oligonucleotide containing 12 to 22 nucleotides, wherein at least one of the nucleotides is modified, the oligonucleotide hybridizes to the nucleic acid sequence of ANGPTL4 (human) of SEQ ID NO: 1, ANGPTL4 (human) of SEQ ID NO: 2, ANGPTL4 (mouse) of SEQ ID NO: 58, and / or ANGPTL4 (mouse) of SEQ ID NO: 59, and the oligonucleotide inhibits the expression of ANGPTL4, as well as to a pharmaceutical composition comprising such an inhibitor and a pharmaceutically acceptable carrier, excipient, diluent, or a combination thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to inhibitors of ANGPTL4, such as antisense oligonucleotides, and pharmaceutical compositions containing such inhibitors, and their use in the treatment of cardiovascular disease, obesity, type II diabetes, homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH) or dyslipidemia.

[0002] 2. Background of the Invention Disturbances in plasma lipids are well-known risk factors in cardiometabolic diseases. Successful treatment of elevated LDL-cholesterol has come since the mid-80s, and in the following decades the focus has been broadened to other lipid classes such as HDL-cholesterol and triglycerides. Epidemiological studies have revealed that increased plasma triacylglycerol (TG) and associated remnant cholesterol are independent risk factors for coronary heart disease (Cullen, 2000). Moreover, hypertriglyceridemia (HTG) is a hallmark of metabolic syndrome (MS), which is often accompanied by obesity and insulin resistance (Reaven, 1995). The increased risk of type 2 diabetes and cardiovascular disease (CVD) associated with metabolic syndrome and HTG suggests that the maintenance of plasma TG homeostasis is highly desirable.

[0003] Patients with severe hypertriglyceridemia may also develop pancreatitis (Athyros, 2002), especially if TG levels exceed 1000-1500 mg / dl (Tsuang, 2009). As many as 40 different genes are now known to regulate plasma TG (Johansen, 2011), but there are also a number of monogenetic disorders known to markedly increase TG (Nordestgaard and Varbo, 2014). These include FCS, which is described in more detail below.

[0004] Lipolysis is a key step in the clearance of TG-rich lipoproteins, which occurs at the luminal surface of capillaries in the heart, skeletal muscle, and adipose tissue. LPL synthesized in muscle and adipocytes is translocated to capillary endothelial cells. Rare genetic defects in lipoprotein lipase (LPL), the main enzyme involved in the hydrolysis of TG on lipoproteins (Benlian, 1996), can cause familial hyperchylomicronemia syndrome (FCS), characterized by plasma TG levels well above 10 mmol. Homozygous defects in apolipoprotein C-II (apoC-II), the main protein activator of LPL, can also cause a similar hypertriglyceridemic phenotype (Breckenridge, 1978). Recently, defects in GPIHBP1, a protein that binds LPL to the surface of endothelial cells (Beigneux, 2007) and mutations in apolipoprotein AV (ApoA-V) (Ishihara, 2005) have also been described to cause hypertriglyceridemia in humans. Genetic defects in the lipase-specific chaperone LMF1 have also been found to promote FCS. Taken together, approximately 2-3 out of 1 million patients have FCS.

[0005] Not only do LPL activators affect the LPL system, but loss-of-function mutations in apoC3 and negative regulators of LPL, such as ANGPTL4, ANGPTL3 or ANGPTL8, have been shown to promote favorable plasma lipid profiles and reduced risk of metabolic diseases. ANGPTL4 is a regulator of various lipases, especially LPL. This protein is an unfolding chaperone that breaks down the dimeric catalytically active form of LPL into an inactive monomer, which is an irreversible event. Compared to apoC3, for example, which dissociates LPL from lipid substrates, ANGPTL is the only known factor that regulates LPL in this way. In addition, ANGPTL4 affects hepatic lipase and endothelial lipase, thereby affecting not only the TG portion of plasma lipids, but also LDL-c and HDL-c. ANGPTL4 is a factor induced during fasting and is expressed not only by the liver but also to an appropriate extent by adipose tissue and skeletal muscle, i.e., ANGPTL4 is ubiquitously expressed. ANGPTL4 expression is regulated by various stimuli, including induction in the liver by Peroxisome Proliferator-Activator Receptor (PPAR) α, PPAR δ, and the glucocorticoid receptor (GR), respectively. Animal models deficient in these ANGPTLs show elevated LPL activity and reduced plasma lipids, while mice with transgenic overexpression of the human mutants show the opposite results. Findings from this animal study are supported by human deletion and loss-of-function mutations, which associate ANGPTL4 with plasma TG levels and HDL-c. The ANGPTL4 gene shows association with cardiometabolic disease.

[0006] Thus, previous information provides new insights into the coordinated activities of LPL, GPIHBP1, ANGPTL and apoA-V in plasma TG homeostasis. Among these factors, ANGPTL4 interestingly also regulates plasma cholesterol levels, i.e., LDL-c, HDL-c and remnant-c, without being completely dependent on the LDL receptor, which is often non-functional in homozygous familial hypercholesterolemia (HoFH) and heterozygous familial hypercholesterolemia (HeFH). This provides an opportunity for "universal" plasma lipid drugs by targeting ANGPTL4.

[0007] ANGPTL4 regulates the activity of lipoprotein lipase, which plays an important role in the uptake of free fatty acids into the liver. Dysregulation of lipoprotein lipase can cause excess lipids in cells, which can lead to, for example, obesity, type II diabetes, or cardiovascular disease.

[0008] ANGPTL4 knockout mice show reduced triglyceride (TG) levels due to increased degradation of very low density lipoprotein (VLDL) and reduced VLDL production. Cholesterol levels are moderately affected. A high lipid diet leads to reduced viability in ANGPTL4 knockout mice treated with monoclonal antibodies due to lipogranulomatous lesions in the intestinal tissue, effluent lymphatic system and / or mesenteric lymph nodes (Desai et al., 2007 PNAS). Humans heterozygous for the ANGPTL4 variant E40K show significantly lower plasma TG levels during fasting. Also, high density lipoprotein (HDL) cholesterol levels were significantly higher in E40K heterozygous humans. As the combination of high TG levels and low HDL cholesterol levels increases the risk of suffering from cardiovascular disease, reducing or inhibiting ANGPTL4 may reduce the risk. ANGPTL4 null alleles are found in humans, but no equivalent pathology has been identified in ANGPTL4 knockout mice to date.

[0009] The oligonucleotides of the present invention that inhibit the expression of ANGPTL4, for example, reduce plasma lipid levels independently of LDL receptor functionality, making them suitable for use in the treatment of, for example, homozygous familial hypercholesterolemia (HoFH) or heterozygous familial hypercholesterolemia (HeFH), which are LDL receptor deficient.

[0010] ANGPTL4 is not only involved in the regulation of fatty acid metabolism, but also in influenza infection. ANGPTL4 is, for example, upregulated by a STAT3-mediated mechanism in influenza pneumonia and is a potential biomarker for respiratory infection and pneumonia (Li et al., Cell Reports 10, Feb. 2015).

[0011] Up to now, there is no antisense oligonucleotide that is highly efficient in reducing and inhibiting ANGPTL4 expression, respectively, and hybridizes with ANGPTL4 mRNA and / or pre-mRNA.The study using siRNA that inhibits ANGPTL4 expression shows that in vivo inhibition is possible only when siRNA is packaged in suitable packaging material.Even when siRNA is packaged, the efficiency of inhibiting mRNA expression often cannot be improved.

[0012] The oligonucleotides of the present invention have been highly successful in inhibiting the expression of ANGPTL4. The mode of action of oligonucleotides is different from that of antibodies or small molecules, and oligonucleotides can be used to inhibit, for example, (i) tissue penetration; (ii) blocking each of multiple target functions and activities; (iii) combinations between oligonucleotides or with antibodies or small molecules, and (iv) inhibition of intracellular effects that are not accessible or specifically accessible to antibodies or that are not inhibitable by small molecules It is highly advantageous in terms of

[0013] Summary of the Invention The present invention relates to an ANGPTL4 inhibitor comprising an oligonucleotide comprising, for example, 12-22 nucleotides, 15-20 nucleotides, or 15, 16, 17, 18, 19, or 20 nucleotides, at least one of the nucleotides being modified. The ANGPTL4 oligonucleotide hybridizes with, for example, the nucleic acid sequence of ANGPTL4 (human; NM_139314) of SEQ ID NO: 1, ANGPTL4 (human; GRCh38_19_8364151_8374373) of SEQ ID NO: 2, ANGPTL4 (mouse; NM_020581.2) of SEQ ID NO: 58, and / or ANGPTL4 (mouse; GRCm38:17:33773750:33781575), and the oligonucleotide inhibits the expression of ANGPTL4. The modified nucleotides are selected from the group consisting of bridged nucleic acids such as LNA, cET, ENA, 2'fluoro modified nucleotides, 2'O-methyl modified nucleotides, 2'O-methoxyethyl modified nucleotides and combinations thereof.

[0014] The ANGPTL4 oligonucleotide of the present invention is, for example, an oligonucleotide sequence selected from the group consisting of positions 1732 to 1759 (e.g., A24044He, SEQ ID NO: 47; A24076He, SEQ ID NO: 47) and / or positions 234 to 261 (e.g., A24102He, SEQ ID NO: 177; A24103He, SEQ ID NO: 178) and / or positions 1264 to 1293 (e.g., A24110He, SEQ ID NO: 185; A24111He, SEQ ID NO: 186) of SEQ ID NO: 1, and / or positions 234 to 261 (e.g., A24102He, SEQ ID NO: 177; A24103He, SEQ ID NO: 178) of SEQ ID NO: 1, and / or positions 1264 to 1293 (e.g., A24110He, SEQ ID NO: 185; A24111He, SEQ ID NO: 186) of SEQ ID NO: 1. It hybridizes with an active site selected from positions 2800 to 2872 (e.g., A24083Hi, SEQ ID NO: 158; A24085Hi, SEQ ID NO: 160; A24086Hi, SEQ ID NO: 161; A24087Hi, SEQ ID NO: 162) and / or positions 3415 to 3442 (e.g., A24089Hi, SEQ ID NO: 164) and / or positions 4968 to 4994 (e.g., A24097Hi, SEQ ID NO: 172) of sequence number 2, or a combination thereof. The inhibitor inhibits the expression of ANGPTL4, for example, at nanomolar or micromolar concentrations.

[0015] The present invention further relates to a pharmaceutical composition comprising the ANGPTL4 inhibitor of the present invention and a pharma- ceutically acceptable carrier, excipient, diluent, or combination thereof.The inhibitor and pharmaceutical composition are each used in a method for preventing and / or treating disorders involving ANGPTL4 imbalance.Such disorders are, for example, cardiometabolic diseases, obesity, diabetes, such as type 2 diabetes, hypercholesterolemia, hypertriglyceridemia (HTG), dyslipidemia, pancreatitis, metabolic syndrome, familial hyperchylomicronemia syndrome (FCS), influenza infection, and / or cancer. Hypercholesterolemia is, for example, homozygous familial hypercholesterolemia (HoFH) and heterozygous familial hypercholesterolemia (HeFH), and cancer is, for example, breast cancer, lung cancer, malignant melanoma, lymphoma, skin cancer, bone cancer, prostate cancer, liver cancer, brain cancer, cancer of the larynx, gallbladder, pancreas, testis, rectum, parathyroid gland, thyroid gland, adrenal gland, nervous tissue, head and neck, colon, stomach, bronchus, kidney, basal cell carcinoma, squamous cell carcinoma, metastatic skin cancer, osteosarcoma, Ewing's sarcoma, reticulum cell sarcoma, liposarcoma, myeloma, giant cell tumor, small cell lung tumor, islet cell tumor, primary brain tumor, meningioma, acute and chronic lymphocytic and granulocytic tumors, acute and chronic myeloid leukemia, hairy cell tumor, adenoma, hyperplasia, medullary carcinoma, intestinal ganglioneuroma, Wilms' tumor, seminoma, ovarian tumor, leiomyoma, tumor), cervical dysplasia, retinoblastoma, soft tissue sarcoma, malignant carcinoid, localized skin lesion, rhabdomyosarcoma, Kaposi's sarcoma, osteogenic sarcoma, malignant hypercalcemia, renal cell tumor, polycythemia vera, adenocarcinoma, anaplastic astrocytoma, glioblastoma multiforme, leukemia, or epidermoid carcinoma.

[0016] The ANGPTL4 inhibitors of the present invention or pharmaceutical compositions comprising an ANGPTL4 inhibitor are administered locally or systemically.

[0017] All documents cited or referenced herein ("references herein"), and all documents cited or referenced in the references herein, together with any manufacturer's instructions, instructions, product specifications and product specifications for any products mentioned herein or in any documents incorporated herein by reference, are hereby incorporated by reference and may be used in the practice of this invention. More specifically, all documents referenced are incorporated by reference to the same extent as if each document was specifically and individually indicated to be incorporated by reference. [Brief description of the drawings]

[0018] [Figure 1] Figure 1: Initial screening of 42 human ANGPTL4-specific antisense oligonucleotides. A control oligonucleotide (Neg1; SEQ ID NO: 57) with no sequence complementarity to any human or mouse mRNA was included as a control. Human epithelioid cervical carcinoma cells (HeLa) were treated with each oligonucleotide at a single concentration of 10 μM for 3 days. Cells were lysed 3 days after the start of treatment and ANGPTL4 and HPRT1 mRNA levels were determined using QuantiGene Singleplex RNA assay. HPRT1 was used as a housekeeping gene for normalization of ANGPTL4 expression. Residual ANGPTL4-mRNA expression relative to mock-treated cells ("no oligo" set as 1). Triplicate wells, mean ± SD (Figure 1). [Diagram 2] FIG. 13 shows another screen of human ANGPTL4-specific antisense oligonucleotides in SK-OV3 cells to investigate residual ANGPTL4 mRNA expression. [Diagram 3] Figure 1 shows additional human ANGPTL4-specific antisense oligonucleotides tested at a concentration of 10 μM in HeLa cells, with four of the antisense oligonucleotides tested showing greater than 50% knockdown of ANGPTL4 mRNA (corresponding to residual mRNA levels of less than 0.5). [Figure 4] FIG. 13 shows another screen of additional ANGPTL4-specific antisense oligonucleotides in SK-OV3 cells to investigate residual ANGPTL4 mRNA expression. [Diagram 5] Figure 1 shows HEK-Blue™ hTLR9 cells used to study stimulation of human TLR9 by monitoring the activation of nuclear factor "kappa light chain enhancer of activated B cells" (NF-kB)-dependent secreted embryonic alkaline phosphatase (SEAP) production in vitro. ANGPTL4 oligonucleotides A24022Hi (SEQ ID NO: 25), A24023Hi (SEQ ID NO: 26), A24071Hi (SEQ ID NO: 54) and A24076He (SEQ ID NO: 47) were analyzed, as well as controls Neg1 (SEQ ID NO: 57) and ODN2006 (5'-TCGTCGTTTTGTCGTTTTGTCGTT-3'PTO modified - Invivogen catalogue number tlrl-2006; SEQ ID NO: 153). [Figure 6] Figure 6 shows human ANGPTL4-specific antisense oligonucleotides A24022Hi (SEQ ID NO: 25), A24023Hi (SEQ ID NO: 26), A24071Hi (SEQ ID NO: 54) and A24076He (SEQ ID NO: 47) with the most potent knockdown efficacy in HeLa and SK-OV3 cells, selected for determination of half maximal inhibitory concentration (IC50) values. Primary hepatocytes were treated with different concentrations (5000nM, 1000nM, 200nM, 40nM, 8nM, 1.6nM) of each ANGPTL4 antisense oligonucleotide for 3 days, and simultaneously treated with PPARγ (1μM). Three days after the start of treatment, mRNA expression was analyzed using QuantiGene Singleplex RNA assay as shown in Figure 6. Mock-treated cells were set to 0.32nM for graphical representation. [Figure 7]Figure 1 shows the first single dose efficacy screen of additional ANGPTL4-specific antisense oligonucleotides (ASOs) in primary hepatocytes. 25000 cells / well were seeded in 96-well collagen I-coated flat-bottom plates and treated with the respective ASOs at a final concentration of 5 μM. To induce ANGPTL4 mRNA expression, cells were treated simultaneously with 1 μM PPARγ. As a vehicle control, cells were treated with the same amount of DMSO ("DMSO"). Every 24 hours, 70 μl of the supernatant was replaced with fresh medium containing PPARγ and 5 μM of the respective ASO or DMSO. After 3 days, cells were lysed and human HPRT1 and human ANGPTL4 mRNA expression was measured using QuantiGene RNA Singleplex assay. ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene HPRT1. Residual ANGPTL4-mRNA expression is shown relative to mock-treated cells ("no oligo" (n=42) set as 1, SD=0.24). Solid and dotted lines indicate 70% and 0% knockdown efficacy, respectively (top graph) or 100% HPRT1 expression in mock-treated cells ("no oligo" (n=42) set as 100, SD=35.8, bottom graph). Data are presented as mean ± SD of triplicate wells. Positive control ASO is indicated by an asterisk. [Figure 8]Figure 1 shows a second single dose efficacy screening of additional ANGPTL4-specific ASOs in primary hepatocytes. 25000 cells / well were seeded in 96-well collagen I-coated flat-bottom plates and treated with each ASO at a final concentration of 5 μM. To induce ANGPTL4 mRNA expression, cells were treated with 1 μM PPARγ at the same time. As vehicle control, cells were treated with the same amount of DMSO ("DMSO") or left untreated ("-DMSO"). Every 24 hours, 70 μl of supernatant was replaced with fresh medium containing PPARγ and 5 μM of each ASO or DMSO or medium alone. After 3 days, cells were lysed and human HPRT1 and human ANGPTL4 mRNA expression was measured using QuantiGene RNA Singleplex assay. ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene HPRT1. Residual ANGPTL4-mRNA expression is shown relative to mock-treated cells ('no oligo' (n=36) set to 1, SD=0.24). Solid and dotted lines indicate 70% and 0% knockdown efficacy (top graph) or 100% HPRT1 expression in mock-treated cells ('no oligo' (n=36) set to 100, SD=19.3, bottom graph), respectively. Data are presented as mean ± SD of sextuplicate (A24076He and negative control oligonucleotides), ninapterate (-DMSO) or triplicate (all other ASO) wells. Positive control ASOs are indicated by asterisks. [Figure 9]Figure 5. NF-kB activation in HEK-Blue hTLR9 SEAP reporter cells. HEK-Blue-hTLR9 cells were seeded in flat-bottom 96-well plates and treated with the indicated oligonucleotides for 24 h. After incubation, cell supernatants were harvested and incubated with QUANTI-Blue solution for 4 h (Figures 9A, 9C, and 9D) or 3.5 h (Figure 9B). SEAP activity was determined by measuring optical density (OD) at 620 nm. Data for cells treated with ANGPTL4-specific ASO and neg1 are shown as mean ± SD of triplicates of OD units relative to the OD units of cells stimulated with 5000 nM ODN2006 (taken as 100%). Data for cells treated with ODN2006 are shown as mean ± SD of sextuplicates (A), mean ± SD of triplicates (D) or mean ± SD of the mean of triplicates on each plate (B, C). [Figure 10] Figure 1 shows IC50 determination of selected ANGPTL4 ASOs. 25000 primary human hepatocytes / well were seeded in 96-well plates and treated with different concentrations (5000nM, 1000nM, 200nM, 40nM, 8nM, 1.6nM) of each ASO. Every 24 hours, 70μl of the supernatant was replaced with fresh medium containing the indicated concentrations of each ASO. After 3 days, cells were lysed and mRNA expression of HPRT1 and ANGPTL4 was measured using QuantiGene RNA Singleplex assay. ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene HPRT1. Residual ANGPTL4-mRNA expression relative to mock-treated cells (set to 1 (n=36), SD=0.26). Data are presented as mean ± SD of triplicate wells. [Figure 11]Figure 1 shows the efficacy of selected ANGPTL4 ASOs on target gene expression after transfection of cynomolgus hepatocytes. 25000 primary cynomolgus hepatocytes / well were seeded in a 96-well plate and transfected with different concentrations (2nM, 0.2nM) of each ASO. After 24 hours of incubation at 37°C, cells were lysed and mRNA expression of HPRT1 and ANGPTL4 was measured using QuantiGene RNA Singleplex assay. ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene HPRT1. Residual ANGPTL4-mRNA expression is shown relative to mock-treated cells (set as 1 (n=12), SD=0.25). Data are presented as the mean ± SD of triplicate wells. [Figure 12] Figure 13 shows mouse embryonic fibroblasts (3T3 cells) treated separately with mouse ANGPTL4-specific antisense oligonucleotides shown in Figure 12 at a single concentration of 10 μM. Three days after the start of treatment, mRNA levels were determined by QuantiGene RNA Singleplex assay. Hprt1 was used as a housekeeping gene for normalization of ANGPTL4 expression. Eight ANGPTL4 antisense oligonucleotides, namely A24047M (SEQ ID NO: 106), A24020M (SEQ ID NO: 79), A24017M (SEQ ID NO: 76), A24021M (SEQ ID NO: 80), A24049M (SEQ ID NO: 108), A24018M (SEQ ID NO: 77), A24041M (SEQ ID NO: 100) and A24010M (SEQ ID NO: 69), reduced normalized ANGPTL4 expression by more than 50%. [Figure 13]Figure 13 shows mouse renal carcinoma Renca cells treated separately with ANGPTL4-specific antisense oligonucleotides shown in Figure 13 at a single concentration of 10 μM. After 3 days, mRNA levels were determined by QuantiGene RNA Singleplex assay. Hprt1 was used as a housekeeping gene for normalization of ANGPTL4 expression. A24020M (SEQ ID NO: 79) and A24019M (SEQ ID NO: 78) caused more than 50% ANGPTL4 knockdown (corresponding to residual mRNA levels of less than 0.5). [Figure 14] 14 shows 9 tested mouse ANGPTL4 specific antisense oligonucleotides and 24 additional mouse ANGPTL4 specific antisense oligonucleotides tested in mouse breast cancer cell 4T1. Without using transfection reagent, cells were treated with 5 μM of each ANGPTL4 antisense oligonucleotide shown in FIG. 14. After 3 days, cell supernatant was replaced with fresh medium containing 5 μM of each ANGPTL4 antisense oligonucleotide and incubated for another 3 days. Then, mRNA level was determined by QuantiGene RNA Singleplex assay. Gapdh was used as a housekeeping gene for normalization of ANGPTL4 expression. Twelve of the antisense oligonucleotides tested, namely A24017M (SEQ ID NO: 76), A24070M (SEQ ID NO: 127), A24020M (SEQ ID NO: 79), A24019M (SEQ ID NO: 78), A24069M (SEQ ID NO: 126), A24021M (SEQ ID NO: 80), A24011M (SEQ ID NO: 70), A24073M (SEQ ID NO: 130), A24018M (SEQ ID NO: 77), A24055M (SEQ ID NO: 114), A24010M (SEQ ID NO: 69) and A24065M (SEQ ID NO: 79), exhibit greater than 80% knockdown of ANGPTL4 mRNA (corresponding to residual mRNA levels of less than 0.2). [Figure 15]15 shows 21 mouse ANGPTL4 specific antisense oligonucleotides tested in 4T1 cells by treating with 5 μM of each ANGPTL4 antisense oligonucleotide shown in FIG. After 3 days, cell supernatant is replaced with fresh medium containing 5 μM of each ANGPTL4 antisense oligonucleotide and incubated for another 3 days. Then, mRNA level is determined by QuantiGene RNA Singleplex assay. Hprt1 is used as a housekeeping gene for normalization of ANGPTL4 expression. A24047M (SEQ ID NO: 106), A24095Mi (SEQ ID NO: 151), A24093Mi (SEQ ID NO: 149), A24020M (SEQ ID NO: 79), A24090Mi (SEQ ID NO: 146) and A24082Mi (SEQ ID NO: 139) show more than 50% knockdown of ANGPTL4 mRNA (corresponding to residual mRNA level of less than 0.5). [Figure 16] Figure 1 shows A24018M (SEQ ID NO: 77), A24019M (SEQ ID NO: 78), A24020M (SEQ ID NO: 79), A24021M (SEQ ID NO: 80), A24047M (SEQ ID NO: 106), A24054M (SEQ ID NO: 113), A24065M (SEQ ID NO: 79), A24070M (SEQ ID NO: 127), A24072M (SEQ ID NO: 129), A24082M (SEQ ID NO: 139) and A24095Mi (SEQ ID NO: 151) with the strongest knockdown efficacy in 3T3, Renca and 4T1 cells, selected for the determination of half maximal inhibitory concentration (IC50) value. 4T1 cells were treated with these ANGPTL4 antisense oligonucleotides at different concentrations (5000nM, 1000nM, 200nM, 40nM, 8nM, 1.6nM) for 3 days. After 3 days, the cell supernatant was replaced with fresh medium containing 5 μM of each ANGPTL4 antisense oligonucleotide and incubated for an additional 3 days. mRNA expression was then analyzed using the QuantiGene Singleplex RNA assay. [Figure 17]Figure 1 shows the first round of single-dose efficacy screening of additional mouse Angptl4-specific ASOs in 4T1 cells. 2500 4T1 cells / well were seeded in 96-well flat-bottom plates and treated with each ASO at a final concentration of 5 μM. After 3 days of treatment, the cell supernatant was replaced with fresh medium containing ASOs and the cells were incubated at 37°C for another 3 days. Cells were then lysed and mouse Hprt1 and mouse Angptl4 mRNA expression was measured using QuantiGene RNA Singleplex assay. Angptl4-mRNA expression values ​​were normalized to the expression of the housekeeping gene Hprt1. Residual Angptl4-mRNA expression is shown relative to mock-treated cells ('no oligo' set to 1 (n=37), SD=0.21). Solid and dotted lines indicate 75% and 0% knockdown efficacy (top graph) or 100% Hprt1 levels (bottom graph) ("no oligo" (n=37) set as 1, SD=0.17), respectively. Data are presented as mean ± SD of triplicate wells. [Figure 18] Figure 2 shows the second single dose screening of mouse Angptl4 specific ASO in Renca cells. 2500 Renca cells / well were seeded in 96-well flat bottom plates and treated with each ASO at a final concentration of 5 μM. After 3 days of treatment, the cell supernatant was replaced with fresh medium containing ASO and the cells were incubated at 37°C for another 3 days. Cells were then lysed and mouse Hprt1 and mouse Angptl4 mRNA expression was measured using QuantiGene RNA Singleplex assay. Angptl4-mRNA expression values ​​were normalized to the expression of the housekeeping gene Hprt1. Residual Angptl4-mRNA expression is shown relative to mock treated cells ("no oligo" (n=37) set to 1, SD=0.37). Solid and dotted lines indicate 75% and 0% knockdown efficacy (top graph) or 100% Hprt1 levels (bottom graph) ("no oligo" (n=37) set to 1, SD=0.36), respectively. Data are presented as the mean ± SD of triplicate wells. [Figure 19]Figure 1. IC50 determination of selected Angptl4 ASOs. 15000 primary mouse hepatocytes / well were seeded in 96-well flat-bottom plates and treated with different concentrations (5000nM, 1000nM, 200nM, 40nM, 8nM, 1.6nM) of each ASO. After 3 days, cells were lysed and Hprt1 and Angptl4 mRNA expression was measured using QuantiGene RNA Singleplex assay. Angptl4-mRNA expression values ​​were normalized to the expression of the housekeeping gene Hprt1. Residual Angptl4-mRNA expression relative to mock-treated cells (set to 1 (n=36), SD=0.17). Neg1 is shown in black. Raw values ​​of Hprt1 relative to no oligo (set to 100 (n=36), SD=13.0) are shown in the bottom graph. Data are presented as mean ± SD of triplicate wells.

[0019] Detailed Description of the Invention The present invention provides a successful inhibitor of ANGPTL4 expression, which is a human or mouse oligonucleotide that hybridizes with the mRNA and / or pre-mRNA sequence of ANGPTL4, and inhibits the expression and activity of ANGPTL4, respectively.The mRNA contains only the exons of the nucleic acid sequence that codes for ANGPTL4, and the pre-mRNA contains the exons and introns of the nucleic acid sequence that codes for ANGPTL4.Therefore, the oligonucleotide of the present invention is an interesting and highly efficient tool that is used in the method of preventing and / or treating the disorder in which ANGPTL4 expression and activity are increased, respectively.

[0020] The elements of the present invention are described in more detail below. Although these elements are listed with specific embodiments, it should be understood that they can be combined in any manner and in any number to create additional embodiments. The various described examples and embodiments should not be interpreted as limiting the present invention only to the embodiments explicitly described. The specification should be understood to support and include embodiments that combine the explicitly described embodiments with various disclosed elements. Furthermore, unless otherwise specified by the context, any permutation and combination of all elements described in this application shall be considered to be disclosed by the specification of this application.

[0021] Throughout this specification and the claims, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising" are understood to imply the inclusion of a stated member, integer or step, or group of members, integers or steps, but not the exclusion of any other member, integer or step, or group of members, integers or steps. The terms "a" and "an" and "the", and similar referents, as used in the context of the present invention (especially in the context of the claims), shall be construed to encompass both the singular and the plural, unless otherwise specified herein or clearly contradicted by context. The recitation of ranges of values ​​herein is merely intended to serve as a shorthand method of individually referring to each value falling within the range. Unless otherwise specified herein, each value is incorporated herein as if it were individually recited herein. All methods described herein can be performed in any suitable order, unless otherwise specified herein or clearly contradicted by context. The use of any examples or exemplary language (e.g., "such as," "for example") presented herein is intended merely to better describe the invention and does not limit the scope of the invention as otherwise claimed. Nothing in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0022] The oligonucleotide inhibitor of the present invention is an antisense oligonucleotide (ASO) consisting of or containing, for example, 10 to 25 nucleotides, 12 to 22 nucleotides, 15 to 20 nucleotides, or 16 to 18 nucleotides. The oligonucleotide consists of or contains, for example, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides.

[0023] For example, the oligonucleotides of the invention form gapmers that consist of or include a central block of at least five nucleotides, i.e., deoxynucleotides and / or ribonucleotides, flanked by nucleotides, e.g., naturally and / or artificially modified deoxynucleotides and / or ribonucleotides.

[0024] The oligonucleotide of the present invention comprises at least one modified nucleotide. The modified nucleotide is, for example, a bridged nucleotide, such as locked nucleic acid (LNA, for example, 2',4'-LNA), cET, ENA, 2'fluoro modified nucleotide, 2'O-methyl modified nucleotide, 2'O-methoxyethyl modified nucleotide, or a combination thereof. In some embodiments, the oligonucleotide of the present invention comprises one or more nucleotides with the same or different modifications. In addition, the oligonucleotide of the present invention optionally comprises a modified phosphate backbone, where the phosphate is, for example, phosphorothioate.

[0025] The oligonucleotides of the present invention include one or more modified nucleotides at the 3' and / or 5' end of the oligonucleotide and / or anywhere within the oligonucleotide, where the modified nucleotides are, for example, tandem of 1, 2, 3, 4, 5 or 6 modified nucleotides, or where the modified nucleotides are combined with one or more unmodified nucleotides. Tables 1-4 below list modified nucleotides, such as LNAs and ( * Examples of ANGPTL4 oligonucleotides that contain phosphorothioates (PTOs) are given below. ANGPTL4 oligonucleotides that consist of or contain the sequences of Table 1 or 2 (human), or Table 3 or 4 (mouse), may contain any other modified nucleotides and / or any other combination of modified and unmodified nucleotides. The ANGPTL4 oligonucleotides of Table 1 hybridize to the mRNA and / or pre-mRNA of human ANGPTL4: [Table 1-1] [Table 1-2] [Table 1-3]

[0026] The ANGPTL4 oligonucleotides in Table 2 also hybridize to human ANGPTL4 mRNA and / or pre-mRNA: [Table 2-1] [Table 2-2] [Table 2-3]

[0027] The oligonucleotides in Table 3 specifically hybridize to mouse ANGPTL4 mRNA and / or pre-mRNA: [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4]

[0028] The oligonucleotides in Table 4 also hybridize specifically to mouse ANGPTL4 mRNA and / or pre-mRNA: [Table 4-1] [Table 4-2]

[0029] The oligonucleotide hybridizes at a hybridizing active area, e.g., a site enriched with highly active ASOs. The hybridizing active area is, for example, one or more regions on the ANGPTL4 mRNA, e.g., SEQ ID NO: 1, and / or the ANGPTL4 pre-mRNA, e.g., SEQ ID NO: 2, where hybridization with the oligonucleotide is likely to result in a strong knockdown of ANGPTL4 expression. In the present invention, for example, it has been surprisingly identified several hybridizing active sites selected from the hybridizing active sites selected from, for example, positions 1732 to 1759 of SEQ ID NO: 1 (e.g., A24044He, SEQ ID NO: 47; A24076He, SEQ ID NO: 47) and / or positions 6603 to 6631 of SEQ ID NO: 2 (e.g., A24022Hi, SEQ ID NO: 25; A24023Hi, SEQ ID NO: 26; A24071Hi, SEQ ID NO: 54). Further hybridization active sites are at positions 234 to 261 (e.g. A24102He, SEQ ID NO: 178; A24103He, SEQ ID NO: 179) and / or positions 1264 to 1293 (e.g. A24110He, SEQ ID NO: 186; A24111He, SEQ ID NO: 187) of human SEQ ID NO: 1, and / or positions 2800 to 2872 (e.g. A24083Hi, SEQ ID NO: 159; A24085Hi, SEQ ID NO: 161; A24086Hi, SEQ ID NO: 162; A24087Hi, SEQ ID NO: 163) and / or positions 3415 to 3442 (e.g. A24089Hi, SEQ ID NO: 165) and / or positions 4968 to 4994 (e.g. A24097Hi, SEQ ID NO: 173) of human SEQ ID NO: 2.The hybridization active site on mouse SEQ ID NO:58 or SEQ ID NO:59 is, for example, at positions 137 to 163 (e.g., A24054M, SEQ ID NO:113) and / or positions 215 to 299 (e.g., A24018M, SEQ ID NO:77; A24019M, SEQ ID NO:78; A24020M, SEQ ID NO:79; A24021M, SEQ ID NO:80; A24065M, SEQ ID NO:79) and / or positions 1343 to 1371 (e.g., A24042M, SEQ ID NO:101; A24043M, SEQ ID NO:102) of SEQ ID NO:58. 109M, SEQ ID NO: 212) and / or positions 1738 to 1771 (e.g. A24047M, SEQ ID NO: 106; A24070M, SEQ ID NO: 127; A24072M, SEQ ID NO: 129), and / or positions 1286 to 1314 of SEQ ID NO: 59 (e.g. A24082Mi, SEQ ID NO: 139; A24125Mi, SEQ ID NO: 226) and / or positions 5485 to 5511 (e.g. A24095Mi, SEQ ID NO: 151; A24148Mi, SEQ ID NO: 151).

[0030] For example, the oligonucleotides of the invention inhibit ANGPTL4, e.g., human or mouse ANGPTL4 expression, by at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. The oligonucleotides of the present invention can inhibit the expression of ANGPTL4 at nanomolar or micromolar concentrations, for example, 0.1 nM to 100 μM, 0.5 nM to 15 nM, 0.6 nM to 10 nM, 1 nM to 10 μM, 5 nM to 5 μM, 10 nM to 1 μM, 15 nM to 950 nM, 20 nM to 900 nM, 25 nM to 850 nM, 30 nM to 800 nM, 35 nM to 750 nM, 40 nM to 700 nM, 45 nM to 650 nM, 50 nM to 500 nM or Inhibited at a concentration range of 40nM to 150nM, or at a concentration of 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900 or 950nM, or at a concentration of 1, 10 or 100μM.

[0031] The ANGPTL4 oligonucleotides of the present invention are used, for example, in a concentration range of 1 nM to 10 μM, 5 nM to 6.6 μM, 10 nM to 5 μM, 15 nM to 3 μM, 20 nM to 2.2 μM, 25 nM to 1 μM, 30 nM to 800 nM, 50 nM to 500 nM, 60 nM to 300 nM, 70 nM to 250 nM, 80 nM to 200 nM, 90 nM to 120 nM, or at a concentration of 1, 1.6, 3, 5, 8, 9, 10, 15, 20, 25, 27, 30, 40, 50, 75, 82, 100, 200, 250, 300, 500 or 740 nM, or at a concentration of 1, 2.2, 3, 5, 6.6 or 10 μM.

[0032] The ANGPTL4 oligonucleotides of the invention are administered, for example, once or repeatedly, e.g., once every 12 hours, once every 24 hours, once every 48 hours, or weekly, once every two weeks, once every three weeks, or monthly, or once every three months, or once every six months, for a period of weeks, months, or years.

[0033] In some embodiments, the present invention relates to a pharmaceutical composition comprising the ANGPTL4 oligonucleotide of the present invention and a pharma- ceutical acceptable carrier, excipient and / or diluent.Optionally, the pharmaceutical composition further comprises a chemotherapeutic agent, another disease-specific active agent, such as insulin, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, another oligonucleotide not of the present invention, an antibody, a HERA fusion protein, a ligand trap, a Fab fragment, a nanobody, a BiTe, and / or a small molecule effective for treating, for example, tumors, diabetes and its side effects, cardiovascular disease, obesity, type II diabetes, hypercholesterolemia, such as homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH), or dyslipidemia.

[0034] The ANGPTL4 oligonucleotide or pharmaceutical composition of the present invention is used in a method for preventing and / or treating disorders, such as disorders involving ANGPTL4 imbalance. Optionally, the use of the oligonucleotide or pharmaceutical composition of the present invention in the method for preventing and / or treating disorders is combined with radiation therapy. Radiation therapy can be further combined with chemotherapy (e.g. platinum, gemcitabine). Disorders are characterized, for example, by ANGPTL4 imbalance, i.e., ANGPTL4 level is elevated compared to the level in normal, healthy cells, tissues, organs or subjects. ANGPTL4 level is elevated, for example, by the increase in ANGPTL4 expression and activity, respectively. ANGPTL4 level is measured by any standard method, such as immunohistochemistry, Western blot, quantitative real-time PCR or QuantiGene assay, known to those skilled in the art.

[0035] The ANGPTL4 oligonucleotide or pharmaceutical composition of the present invention is administered locally or systemically, for example, orally, sublingually, nasally, subcutaneously, intravenously, intraperitoneally, intramuscularly, intratumorally, intrathecally, transdermally and / or rectally.Alternatively or in combination, ex vivo treated immune cells are administered.ANGPTL4 oligonucleotide is administered alone or in combination with another ANGPTL4 antisense oligonucleotide of the present invention, optionally in combination with another compound such as another oligonucleotide not of the present invention, antibody, HERA fusion protein, ligand trap, Fab fragment, nanobody, BiTe, small molecule and / or chemotherapeutic drug (e.g. platinum, gemcitabine), and / or another disease-specific drug such as insulin, angiotensin converting enzyme inhibitor and / or angiotensin receptor blocker.

[0036] The oligonucleotides, antibodies, HERA fusion proteins, ligand traps, Fab fragments, nanobodies, BiTes and / or small molecules not of the invention are effective in preventing and / or treating tumors, influenza infections, diabetes, such as type II diabetes, and its side effects, cardiovascular disease, obesity, hypercholesterolemia, such as homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH), or dyslipidemia. The ANGPTL4 oligonucleotides or pharmaceutical compositions of the invention are used in methods for preventing and / or treating, for example, solid tumors or hematological tumors. Examples of cancers which can be prevented and / or treated using the oligonucleotides or pharmaceutical compositions of the present invention include breast cancer, lung cancer, malignant melanoma, lymphoma, skin cancer, bone cancer, prostate cancer, liver cancer, brain cancer, cancer of the larynx, gallbladder, pancreas, testis, rectum, parathyroid gland, thyroid gland, adrenal gland, nervous tissue, head and neck, colon, stomach, bronchus, kidney, basal cell carcinoma, squamous cell carcinoma, metastatic skin cancer, osteosarcoma, Ewing's sarcoma, reticulum cell sarcoma, liposarcoma, myeloma, giant cell tumor, small cell lung tumor, islet cell tumor, primary brain tumor, meningiomas, acute and chronic lymphocytic and granulocytic tumors, acute and chronic myeloid leukemias, hairy cell tumors, adenomas, hyperplasias, medullary carcinomas, intestinal ganglioneuromas, Wilms' tumors, seminoma, ovarian tumors, leiomyomas, cervical dysplasias, retinoblastomas, soft tissue sarcomas, malignant carcinoids, localized skin lesions, rhabdomyosarcomas, Kaposi's sarcoma, osteogenic sarcomas, malignant hypercalcemia, renal cell tumors, polycythemia vera, adenocarcinomas, anaplastic astrocytoma, glioblastoma multiforme, leukemias or epidermoid carcinomas.

[0037] Further examples of diseases other than cancer that can be prevented and / or treated using the ANGPTL4 oligonucleotides or pharmaceutical compositions of the present invention are diabetes and its side effects, such as type II diabetes, cardiovascular disease, obesity, hypercholesterolemia, such as homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH), or dyslipidemia.

[0038] In some examples, two or more ANGPTL4 oligonucleotides of the present invention are administered together at the same time, for example in a pharmaceutical composition or separately, or at staggered intervals.In some examples, two or more ANGPTL4 oligonucleotides of the present invention are administered together at the same time, for example in a pharmaceutical composition or separately, or at staggered intervals.In other examples, one or more oligonucleotides of the present invention are administered together with another compound, such as another oligonucleotide, antibody, HERA fusion protein, ligand trap, Fab fragment, nanobody, BiTe, small molecule and / or chemotherapeutic agent that is not the present invention, at the same time, for example in a pharmaceutical composition or separately, or at staggered intervals.

[0039] The subject of the present invention is, for example, a mammal, a bird or a fish.

[0040] Working Example The following examples illustrate various embodiments of the present invention, but the present invention is not limited to these examples. The following experiments were performed on cells that endogenously express ANGPTL4, i.e., the cells are not artificial systems that contain transfected reporter constructs. Such artificial systems generally show higher inhibition and lower IC than endogenous systems, which are closer to the therapeutically relevant in vivo system. 50 Furthermore, no transfection agent was used in the following experiments, i.e. gymnotic delivery was performed. Transfection agents increase the activity of oligonucleotides, which leads to IC 50It is known that the transfection agent affects the value (for example, see Zhang et al., Gene Therapy, 2011, 18, 326-333; Stanton et al., Nucleic Acid Therapeutics, Vol. 22, NO. 5, 2012). Because it is difficult or impossible to convert artificial systems using transfection agents into therapeutic approaches, and transfection agents have not been approved for oligonucleotides so far, the following experiments are performed without transfection agents, except for the experiment in Example 11, which uses a transfection agent.

[0041] Example 1: First round screening of human ANGPTL4-specific antisense oligonucleotides in HeLa cells 5000 HeLa cells / well were seeded in a 96-well plate and treated with each antisense oligonucleotide shown in FIG. 1 at a final concentration of 10 μM. To induce ANGPTL4 mRNA expression, cells were simultaneously treated with 1 μM PPARδ (Sigma Aldrich, Cat. No. SML1491). The PPARδ used in this example is based on a PPARδ stock solution (10 mM) prepared by dissolving, for example, 5 mg of PPARδ (molecular weight: 453.50) in 1.1 ml of DMSO. For a final concentration of 1 μM PPARδ, cells seeded in a 96-well plate were incubated with 100 μl of medium supplemented with 0.01 μl of PPARδ stock solution. As a negative control, cells were treated with the same volume of DMSO. Three days after the start of treatment, cells were lysed and human HPRT1 and human ANGPTL4 mRNA expression was measured using the QuantiGene RNA Singleplex assay (FIG. 1). The QuantiGene assay used in this example is based on branched DNA technology (bDNA), which relies on coordinate hybridization of target mRNA with a specific probe set (part of the QuantiGene Reagent System). The assay is performed according to the manufacturer's protocol (Thermo Fisher Scientific) and is used to determine RNA levels. It combines the QuantiGene Sample Processing Kit, which is used for cell lysis, with the QuantiGene Reagent System, which is used for hybridization, amplification and detection of the RNA of interest. The QuantiGene Reagent System is based on an RNA-specific probe set designed to detect a specific RNA of interest.

[0042] ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene HPRT1. Residual ANGPTL4-mRNA expression is shown relative to mock-treated cells ("no oligo" set to 1). Solid and dotted lines indicate 70% and 50% or 0% knockdown efficacy, respectively. Data are presented as the mean ± SD of triplicate wells.

[0043] As shown in Figure 1, two antisense oligonucleotides (A24022Hi (SEQ ID NO: 25) and A24023Hi (SEQ ID NO: 26)) reduced normalized ANGPTL4 expression by more than 70% (corresponding to residual mRNA levels of less than 0.3). In addition, three antisense oligonucleotides (A24003He (SEQ ID NO: 5), A24042He (SEQ ID NO: 45), and A24005Hi (SEQ ID NO: 7)) showed knockdown efficacy of 70% to 50%, and the control oligonucleotide (Neg1) did not reduce ANGPTL4 mRNA expression.

[0044] Example 2: Secondary screening of human ANGPTL4-specific antisense oligonucleotides in SK-OV3 cells 5000 SK-OV3 cells / well were seeded in 96-well plates and treated with each ANGPTL4 antisense oligonucleotide at a final concentration of 10 μM. To induce ANGPTL4 mRNA expression, cells were simultaneously treated with 1 μM PPARδ (Sigma Aldrich, Catalog No. SML1491; see Example 1 for preparation of 10 mM stock solution). For a final concentration of 1 μM PPARδ, cells seeded in 96-well plates were incubated with 100 μl of medium supplemented with 0.01 μl of PPARδ stock solution. As a negative control, cells were treated with the same volume of DMSO.

[0045] Cells were lysed 3 days after the start of treatment and human HPRT1 and human ANGPTL4 mRNA expression was measured using the QuantiGene RNA Singleplex assay. ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene HPRT1. Residual ANGPTL4-mRNA expression relative to mock-treated cells ("no oligo" set to 1) is shown in Figure 2. Solid and dotted lines indicate 60% and 0% knockdown efficacy, respectively. Data are presented as the mean ± SD of triplicate wells.

[0046] Repeated ANGPTL4 antisense oligonucleotide screening in SK-OV3 cells yielded three ANGPTL4 antisense oligonucleotides (A24022Hi (sequence number 25), A24044He (sequence number 47), A24023Hi (sequence number 26)) with knockdown efficiency of greater than 60%.

[0047] Example 3: First single-dose efficacy screen of additional human ANGPTL4-specific antisense oligonucleotides in HeLa cells 5000 HeLa cells / well were seeded in 96-well plates and treated with the most efficient ANGPTL4 antisense oligonucleotides (A24022Hi (SEQ ID NO: 25), A24023Hi (SEQ ID NO: 26), A24044He (SEQ ID NO: 47)) from the first round of screening in HeLa (Figure 1) and SK-OV3 (Figure 2) and additional ANGPTL4-specific antisense oligonucleotides (A24071Hi (SEQ ID NO: 54), A24076He (SEQ ID NO: 47), A24075He (SEQ ID NO: 5), A24073Hi (SEQ ID NO: 55), A24065Hi (SEQ ID NO: 51), A24067Hi (SEQ ID NO: 52), A24077He (SEQ ID NO: 47), A24074Hi (SEQ ID NO: 56)) at a final concentration of 10 μM. To induce ANGPTL4 mRNA expression, cells were simultaneously treated with 1 μM PPARδ (Sigma Aldrich, Catalog No. SML1491; see Example 1 for preparation of 10 mM stock solution). For a final concentration of 1 μM PPARδ, cells seeded in a 96-well plate were incubated with 100 μl of medium supplemented with 0.01 μl of PPARδ stock solution. As a negative control, cells were treated with the same volume of DMSO.

[0048] Cells were lysed 3 days after the start of treatment and human HPRT1 and human ANGPTL4 mRNA expression was measured using the QuantiGene RNA Singleplex assay. ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene HPRT1. Residual ANGPTL4-mRNA expression relative to mock-treated cells ("no oligo" set to 1) is shown in Figure 3. Solid and dotted lines indicate 50% and 0% knockdown efficacy, respectively. Data are presented as the mean ± SD of triplicate wells.

[0049] As shown in Figure 3, four of the ANGPTL4 antisense oligonucleotides tested (A24022Hi (sequence number 25), A24023Hi (sequence number 26), A24044He (sequence number 47), and A24071Hi (sequence number 54)) showed greater than 50% knockdown of ANGPTL4 mRNA (corresponding to residual mRNA levels of less than 0.5), and treatment with the Neg1 negative control oligonucleotide did not result in a reduction in ANGPTL4 mRNA levels.

[0050] Example 4: Second single-dose efficacy screen of additional human ANGPTL4-specific antisense oligonucleotides in SK-OV3 cells 5000 SK-OV3 cells / well were seeded in a 96-well plate and treated with each ANGPTL4 antisense oligonucleotide (A24071Hi (SEQ ID NO: 54), A24022Hi (SEQ ID NO: 25), A24076He (SEQ ID NO: 47), A24044He (SEQ ID NO: 47), A24023Hi (SEQ ID NO: 26), A24077He (SEQ ID NO: 47), A24075He (SEQ ID NO: 5), A24073Hi (SEQ ID NO: 55)) at a final concentration of 10 μM. To induce ANGPTL4 mRNA expression, the cells were simultaneously treated with 1 μM PPARδ (Sigma Aldrich, Catalog No. SML1491; see Example 1 for preparation of 10 mM stock solution). For a final concentration of 1 μM PPARδ, cells seeded in a 96-well plate were incubated with 100 μl of medium supplemented with 0.01 μl of PPARδ stock solution. As a negative control, cells were treated with the same volume of DMSO.

[0051] Cells were lysed 3 days after the start of treatment and human HPRT1 and human ANGPTL4 mRNA expression was measured using the QuantiGene RNA Singleplex assay. ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene HPRT1. Residual ANGPTL4-mRNA expression relative to mock-treated cells ("no oligo" set to 1) is shown in Figure 4. Solid and dotted lines indicate 50% and 0% knockdown efficacy, respectively. Data are presented as the mean ± SD of triplicate wells.

[0052] Repeated optimization of ANGPTL4-specific antisense oligonucleotide screening in SK-OV3 cells yielded five ANGPTL4 antisense oligonucleotides (A24071Hi (sequence number 54), A24022Hi (sequence number 25), A24076He (sequence number 47), A24044He (sequence number 47), A24023Hi (sequence number 26)) with knockdown efficiency of greater than 50% (Figure 4).

[0053] Example 5: In vitro TLR9 assay of selected human ANGPTL4-specific antisense oligonucleotides Binding of immune stimulatory ligands, such as bacterial DNA or immune stimulatory oligonucleotides with or without unmethylated CpG dinucleotides, results in TLR activation. Because immune activation can lead to severe and potentially fatal pathologies of excessive cytokine release, there is an urgent need for preclinical testing systems that predict cytokine release in humans.

[0054] HEK-Blue-hTLR9 (Invivogen Catalog No. hkb-htlr9) cells were seeded in flat-bottom 96-well plates and treated with ANGPTL4 oligonucleotides A24022Hi (SEQ ID NO: 25), A24023Hi (SEQ ID NO: 26), A24071Hi (SEQ ID NO: 54) and A24076He (SEQ ID NO: 47) for 24 hours. Cell supernatants were then harvested and incubated with QUANTI-Blue solution (Invivogen Catalog No. rep-qbs) for 4 hours. SEAP activity was determined by measuring optical density. The mean and standard deviation of OD units relative to OD units (set at 100) of cells stimulated with 5000 nM ODN2006 are shown in Figure 5. Data are presented as the mean ± SD of triplicate wells.

[0055] As shown in Figure 5, none of the ANGPTL4-specific antisense oligonucleotides tested induced TLR9 activation. In contrast, the positive control CpG oligonucleotide ODN2006 (5'-TCGTCGTTTTGTCGTTTTGTCGTT-3'PTO modified - Invivogen catalog number tlrl-2006; SEQ ID NO: 153) clearly stimulated NFκB activation (Figure 5).

[0056] Example 6: IC of selected human ANGPTL4-specific antisense oligonucleotides 50 decision 30000 primary human hepatocytes / well were seeded in 96-well plates and treated with various ANGPTL4 antisense oligonucleotides: A24022Hi (SEQ ID NO: 25), A24023Hi (SEQ ID NO: 26), A24071Hi (SEQ ID NO: 54) and A24076He (SEQ ID NO: 47) at various concentrations of 5000nM, 1000nM, 200nM, 40nM, 8nM and 1.6nM. To induce ANGPTL4 mRNA expression, cells were simultaneously treated with 1μM PPARγ (Sigma Aldrich, Catalog No. R2408). PPARγ stock solution (10mM) was prepared by dissolving 10mg PPARγ (molecular weight: 357.43) in 2.8ml DMSO. For a final concentration of 1 μM PPARγ, cells seeded in 96-well plates were incubated with 100 μl of medium supplemented with 0.01 μl PPARγ stock solution. As a negative control, cells were treated with the same volume of DMSO. Every 24 h, 70 μl of the supernatant was replaced with fresh medium containing 1 μM PPARγ and the respective ANGPTL4 antisense oligonucleotide at the indicated concentration. Three days after the start of treatment, cells were lysed and the mRNA expression of HPRT1 and ANGPTL4 was measured using the QuantiGene RNA Singleplex assay. ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene HPRT1. Residual ANGPTL4-mRNA expression relative to mock-treated cells (set at 1). For graphical presentation, mock-treated cells were set at 0.32 nM. Data are presented as the mean ± SD of triplicate wells.

[0057] From Figure 6 and Table 5, the selected ANGPTL4-specific antisense oligonucleotides suppressed ANGPTL4 mRNA expression with IC in the nanomolar range. 50 It is demonstrated that the inhibition is dose-dependent at high values.

[0058] [Table 5]

[0059] Example 7: First single dose screening of additional human ANGPTL4-specific antisense oligonucleotides (ASOs) in primary hepatocytes A total of 49 additional ANGPTL4-specific antisense oligonucleotides were designed. Based on two initial rounds of screening in human cell lines (data not shown), 17 promising ASOs were selected for a first round of screening in primary human hepatocytes (Figure 7). Three control oligonucleotides (R01002, R01014, Neg1) of different lengths (16, 17 and 18 nucleotides, respectively) with no sequence complementarity to any human or mouse mRNA were included as negative controls, and three ANGPTL4-specific oligonucleotides with confirmed knockdown efficiency were used as positive controls (A24022Hi (SEQ ID NO: 25), A24071Hi (SEQ ID NO: 54), A24076He (SEQ ID NO: 47)). Human primary hepatocytes (Lonza) were treated with each oligonucleotide at a single concentration of 5 μM for 3 days without the use of transfection reagent. To induce ANGPTL4 mRNA expression, cells were simultaneously treated with 1 μM PPARγ (Sigma Aldrich, Catalog No. R2408; see Example 6 for preparation of 10 mM stock solution).For a final concentration of 1 μM PPARγ, cells seeded in 96-well plates were incubated with 100 μl of medium supplemented with 0.01 μl of PPARγ stock solution.As a negative control, cells were treated with the same volume of DMSO.

[0060] Three days after the start of treatment, cells were lysed and mRNA levels were determined by QuantiGene RNA Singleplex assay. Hypoxanthine phosphoribosyltransferase 1 (HPRT1) was used as a housekeeping gene for normalization of ANGPTL4 expression. As shown in Figure 7, PPARγ stimulation resulted in an approximately 50% increase in ANGPTL4 levels compared to DMSO-treated cells (no oligo).

[0061] Treatment with eight ANGPTL4-specific ASOs (A24096Hi (SEQ ID NO: 172), A24103He (SEQ ID NO: 179), A24091Hi (SEQ ID NO: 167), A24123He (SEQ ID NO: 197), A24083Hi (SEQ ID NO: 159), A24087Hi (SEQ ID NO: 163), A24102He (SEQ ID NO: 178), A24116He (SEQ ID NO: 192)) and positive control ASOs (A24022Hi (SEQ ID NO: 25), A24071Hi (SEQ ID NO: 54), A24076He (SEQ ID NO: 47)) reduced ANGPTL4 expression by more than 70% (corresponding to a residual ANGPTL4-mRNA expression of less than 0.3). Control oligonucleotides (Neg1, R01002, R01014) did not reduce ANGPTL4 mRNA expression.

[0062] Example 8: Second single-dose screening of additional human ANGPTL4-specific antisense oligonucleotides (ASOs) in primary hepatocytes The remaining newly designed ANGPTL4-specific ASOs were tested in primary hepatocytes under the experimental conditions of Example 7 (Figure 8). These ASOs were well tolerated in subsequent in vitro tests (data not shown). One ANGPTL4-specific oligonucleotide with confirmed knockdown efficiency was used as a positive control (A24076He (SEQ ID NO: 47)), and three control oligonucleotides of different lengths (16, 17 and 18 nucleotides, respectively) that do not have sequence complementarity to any human or mouse mRNA (R01009, R01019, Neg1) were included as negative controls.

[0063] Treatment with ten ANGPTL4-specific ASOs (A24083Hi (sequence number 159), A24089Hi (sequence number 165), A24117He (sequence number 193), A24124He (sequence number 46), A24103He (sequence number 179), A24097Hi (sequence number 173), A24110He (sequence number 186), A24121He (sequence number 195), A24086Hi (sequence number 162), A24085Hi (sequence number 161)) reduced ANGPTL4 expression by more than 70% (corresponding to a residual ANGPTL4-mRNA expression of less than 0.3), while incubation with the positive control ASO A24076H reduced ANGPTL4 mRNA expression by approximately 63% (Figure 8). Control oligonucleotides (Neg1, R01009, R01019) only modestly (6–20%) reduced ANGPTL4 mRNA expression.

[0064] Example 9: Activation of human Toll-like receptor 9 (hTLR9) in response to human angiopoietin-like protein 4 (ANGPTL4)-specific LNA-modified antisense oligonucleotides The potential of human ANGPTL4-specific LNA-modified antisense oligonucleotides A24076H (SEQ ID NO: 47), A24083Hi (SEQ ID NO: 159), A24085Hi (SEQ ID NO: 161), A24086Hi (SEQ ID NO: 162), A24087Hi (SEQ ID NO: 163), A24089Hi (SEQ ID NO: 165), A24096Hi (SEQ ID NO: 172), A24102He (SEQ ID NO: 178), A24103He (SEQ ID NO: 179), A24110He (SEQ ID NO: 186), A24111He (SEQ ID NO: 187), A24113He (SEQ ID NO: 189), A24116He (SEQ ID NO: 192) and A24123He (SEQ ID NO: 197) to activate TLR9 was tested. Experiments were performed once (A24076H, A24096H, A24102He, A24113He, A24116He and A24123He) or twice (all other ASOs) in HEK-Blue-hTLR9 cells (Invivogen catalog number hkb-htlr9), a TLR9 reporter cell line, under the experimental conditions of Example 5. As shown in Figures 9A, 9B, 9C and 9D, no dose-dependent activation of NF-κB was observed after treatment of cells with different concentrations of each human ANGPTL4 ASO. In contrast, NF-κB was activated in a dose-dependent manner after treatment with positive control ODN2006 (5'-TCGTCGTTTTGTCGTTTTGTCGTT-3'PTO modified - Invivogen catalog number tlrl-2006; SEQ ID NO: 153).

[0065] Example 10: IC of selected human ANGPTL4-specific antisense oligonucleotides (ASOs) 50 decision Based on knockdown efficiency in primary hepatocytes (Figures 7 and 8), the ASO with the strongest knockdown efficacy and showing no induction of caspase 3 / 7 after transfection (data not shown) was selected as IC 50 As a positive control, ANGPTL4-specific ASO A24076He (SEQ ID NO: 47), whose knockdown efficiency was confirmed, was used.

[0066] Primary human hepatocytes (Primacyt) were treated with different concentrations of ANGPTL4-specific ASO or negative control oligonucleotides Neg1, R01009 and R01019 for 3 days. At the same time, cells were treated with PPARγ (1 μM) (Sigma Aldrich, Catalog No. R2408; see Example 6 for preparation of 10 mM stock solution) to induce ANGPTL4 expression. For a final concentration of 1 μM PPARγ, cells seeded in a 96-well plate were incubated with 100 μl of medium supplemented with 0.01 μl of PPARγ stock solution. As a negative control, cells were treated with the same volume of DMSO. After 3 days, mRNA expression was analyzed using QuantiGene Singleplex RNA assay.

[0067] Table 6 and FIG. 10 show that eight ANGPTL4-specific ASOs (A24083Hi (SEQ ID NO: 159), A24085Hi (SEQ ID NO: 161), A24087Hi (SEQ ID NO: 163), A24089Hi (SEQ ID NO: 165), A24097Hi (SEQ ID NO: 173), A24103He (SEQ ID NO: 179), A24110He (SEQ ID NO: 186), and A24111He (SEQ ID NO: 187)) and the positive control A24076He (SEQ ID NO: 47) suppressed ANGPTL4 mRNA expression with IC in the nanomolar range. 50 Treatment with ASO A24086Hi (SEQ ID NO: 162) did not result in a dose-dependent decrease in ANGPTL4 mRNA expression (R 2 = 0.5), therefore the data were not included.

[0068] Table 6 below lists the IC of selected human ANGPTL4-specific antisense oligonucleotides determined in primary human hepatocytes. 50 Value and R 2 Shows. * is R 2 is less than 0.85.

[0069] [Table 6]

[0070] Example 11: In vitro efficacy of human ANGPTL4-specific oligonucleotides in cynomolgus monkey hepatocytes Human ANGPTL4-specific antisense oligonucleotide A24076H (SEQ ID NO: 47), which shows in vivo tolerance, and three additional human ANGPTL4-specific ASOs (Table 7) with only one mismatch to the cynomolgus monkey ANGPTL4 sequence were tested in primary cynomolgus monkey hepatocytes (Figure 11). All tested ASOs were shown to confirm knockdown efficiency in human cell lines and primary hepatocytes. Two control oligonucleotides (R01009, R01019) of different lengths (16 and 17 nucleotides, respectively) that do not have sequence complementarity to any human or mouse RNA were included as negative controls.

[0071] Table 7 shows human ANGPTL4-specific ASOs with proven knockdown efficiency in human cells that do not cause caspase 3 / 7 induction in vitro. CrossReact and number of mismatches with cynomolgus (Mfa, macaca fascicularis) ANGPTL4 sequence, as well as activity in primary cynomolgus hepatocytes in vitro (Figure 11): [Table 7]

[0072] Primary cynomolgus hepatocytes (Primacyt) were transfected with different concentrations of ANGPTL4-specific ASO or negative control oligonucleotides R01009 and R01019 for 3 days. At the same time, cells were treated with PPARδ (1 μM) (Sigma Aldrich, Catalog No. R2408; see Example 6 for preparation of 10 mM stock solution) to induce ANGPTL4 expression. For PPARγ at a final concentration of 1 μM, cells seeded in 96-well plates were incubated with 100 μl of medium supplemented with 0.01 μl of PPARγ stock solution. As a negative control, cells were treated with the same volume of DMSO. After 3 days, mRNA expression was analyzed using QuantiGene Singleplex RNA assay.

[0073] As shown in Figure 11, treatment with PPARδ induced ANGPTL4 expression by approximately 8-fold (Figure 11, DMSO control). Treatment with ANGPTL4-specific ASO A24076He (SEQ ID NO: 47), which is fully cross-reactive with the cynomolgus monkey ANGPTL4 sequence, resulted in more than 70% knockdown of ANGPTL4 (corresponding to a residual mRNA expression of 0.3). In addition, human ANGPTL4-specific oligonucleotides with one mismatch with the cynomolgus monkey sequence (A24089Hi (SEQ ID NO: 165), A24110He (SEQ ID NO: 186), A24111He (SEQ ID NO: 187)) reduced cynomolgus monkey ANGPTL4 mRNA by up to 51% (corresponding to a residual ANGPTL4-mRNA expression of 0.49). The negative control oligonucleotide R01009 did not reduce Angptl4 expression in primary cynomolgus monkey hepatocytes, while the control oligonucleotide R01019 only slightly reduced ANGPTL4 mRNA expression by approximately 25% when used at a concentration of 2 nM (corresponding to a residual ANGPTL4-mRNA expression of 0.75).

[0074] Conclusions based on Example 11: Taken together, our in vitro experiments identified a highly potent human ANGPTL4-specific ASO suitable for testing ASO-based ANGPTL4-targeted therapeutics in cynomolgus monkeys, for example for the systemic treatment of patients with dyslipidemia to reduce ANGPTL4-mediated inhibition of lipoprotein lipase L and prevent cellular lipid overload, obesity, type II diabetes and cardiovascular disease.

[0075] Example 12: First single dose screening of mouse ANGPTL4-specific antisense oligonucleotides in 3T3 cells 4500 3T3 cells / well were seeded in 96-well plates and treated with ANGPTL4 antisense oligonucleotides shown in Figure 12 at a final concentration of 10 μM. Cells were lysed and mouse Hprt1 and mouse ANGPTL4 mRNA expression was measured using QuantiGene RNA Singleplex assay. ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene Hprt1. Residual ANGPLT4-mRNA expression relative to mock-treated cells ("no oligo" set to 100) is shown in Figure 12. Solid and dotted lines indicate 50% and 0% knockdown efficacy, respectively. Data are presented as mean ± SD of triplicate wells.

[0076] As shown in FIG. 12, eight ANGPTL4 antisense oligonucleotides, namely, A24047M (sequence number 106), A24020M (sequence number 79), A24017M (sequence number 76), A24021M (sequence number 80), A24049M (sequence number 108), A24018M (sequence number 77), A24041M (sequence number 100) and A24010M (sequence number 69), reduced normalized ANGPTL4 expression by more than 50%, while the control oligonucleotide (Neg1) did not reduce ANGPTL4 mRNA expression (FIG. 12).

[0077] Example 13: Second single-dose efficacy screen of mouse ANGPTL4-specific antisense oligonucleotides in Renca cells 5000 Renca cells / well were seeded in 96-well plates and treated with ANGPTL4 antisense oligonucleotides shown in FIG. 13 at a final concentration of 10 μM. Three days after the start of treatment, cells were lysed and mouse Hprt1 and mouse ANGPTL4 mRNA expression was measured using QuantiGene RNA Singleplex assay. ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene Hprt1. Residual ANGPTL4-mRNA expression is shown relative to mock-treated cells ("no oligo" set to 1). Solid and dotted lines indicate 50% and 0% knockdown efficacy, respectively. Data are presented as mean ± SD of triplicate wells.

[0078] As shown in Figure 13, treatment with two ANGPTL4-specific antisense oligonucleotides, namely A24020M (sequence number 79) and A24019M (sequence number 78), resulted in greater than 50% ANGPTL4 knockdown (corresponding to residual mRNA levels of less than 0.5) (Figure 13).

[0079] Example 14: Testing of additional mouse ANGPTL4-specific antisense oligonucleotides in 4T1 cells 2500 4T1 cells / well were seeded in 96-well plates and treated with ANGPTL4 antisense oligonucleotides (ASOs) shown in FIG. 14 at a final concentration of 5 μM. After 3 days, cell supernatants were replaced with fresh medium containing ASOs. Six days after the start of treatment, cells were lysed and mouse Gapdh and mouse ANGPTL4 mRNA expression was measured using QuantiGene RNA Singleplex assay. ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene Gapdh. Residual ANGPTL4-mRNA expression relative to Neg1-treated cells (set as 1) is shown. Solid and dotted lines indicate 80% and 0% knockdown efficacy, respectively. Data are presented as mean ± SD of triplicate wells.

[0080] As shown in FIG. 14, twelve of the antisense oligonucleotides tested, namely, A24017M (SEQ ID NO: 76), A24070M (SEQ ID NO: 127), A24020M (SEQ ID NO: 79), A24019M (SEQ ID NO: 78), A24069M (SEQ ID NO: 126), A24021M (SEQ ID NO: 80), A24011M (SEQ ID NO: 70), A24073M (SEQ ID NO: 130), A24018M (SEQ ID NO: 77), A24055M (SEQ ID NO: 114), A24010M (SEQ ID NO: 69) and A24065M (SEQ ID NO: 79), show greater than 80% knockdown of ANGPTL4 mRNA (corresponding to residual mRNA levels of less than 0.2).

[0081] Example 15: Single-dose efficacy screening of intron-targeted mouse ANGPTL4-specific antisense oligonucleotides in 4T1 cells 2500 4T1 cells / well were seeded in 96-well plates and treated with ANGPTL4 antisense oligonucleotides (ASOs) shown in Figure 15 at a final concentration of 5 μM. Three days after the start of treatment, cell supernatants were replaced with fresh medium containing ASOs and cells were incubated for another 3 days. Cells were then lysed and mouse Hprt1 and mouse ANGPTL4 mRNA expression was measured using QuantiGene RNA Singleplex assay. ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene Hprt1. Residual ANGPTL4-mRNA expression relative to mock-treated cells ("no oligo" control set to 1) is shown. Solid and dotted lines indicate 50% and 0% knockdown efficacy, respectively. Data are presented as mean ± SD of triplicate wells.

[0082] As shown in Figure 15, six of the ANGPTL4 antisense oligonucleotides tested, namely A24047M (sequence number 106), A24095Mi (sequence number 151), A24093Mi (sequence number 149), A24020M (sequence number 79), A24090Mi (sequence number 146) and A24082Mi (sequence number 139), showed greater than 50% knockdown of ANGPTL4 mRNA (corresponding to residual mRNA levels of less than 0.5).

[0083] Example 16: IC of selected mouse ANGPTL4-specific antisense oligonucleotides 50 decision 2500 4T1 cells / well were seeded in a 96-well plate and treated with each of the ANGPTL4 antisense oligonucleotides (ASOs) A24018M (SEQ ID NO: 77), A24019M (SEQ ID NO: 78), A24020M (SEQ ID NO: 79), A24021M (SEQ ID NO: 80), A24047M (SEQ ID NO: 106), A24054M (SEQ ID NO: 113), A24065M (SEQ ID NO: 79), A24070M (SEQ ID NO: 127), A24072M (SEQ ID NO: 129), A24082M (SEQ ID NO: 139) and A24095Mi (SEQ ID NO: 151) at various concentrations of 5000 nM, 1000 nM, 200 nM, 40 nM, 8 nM and 1.6 nM. Three days after the start of treatment, the cell supernatant was replaced with fresh medium containing ASO, and the cells were incubated for another 3 days. Cells were then lysed, and the mRNA expression of mouse Hprt1 and mouse ANGPTL4 was measured using QuantiGene RNA Singleplex assay. ANGPTL4-mRNA expression values ​​were normalized to the expression of the housekeeping gene Hprt1. Residual ANGPTL4-mRNA expression is shown relative to mock-treated cells ("no oligo" control set as 1). Data are presented as the mean ± SD of triplicate wells.

[0084] From Figure 16 and Table 8, it can be seen that the selected ANGPTL4-specific antisense oligonucleotides suppressed ANGPTL4 mRNA expression with IC in the nanomolar range. 50 It is demonstrated that the inhibition is dose-dependent at high values.

[0085] [Table 8]

[0086] Example 17: First single dose screening of additional mouse Angptl4-specific ASOs in 4T1 cells Mouse Angptl4-specific antisense oligonucleotides were designed. In the initial screening, 53 ASOs targeting Angptl4 mRNA were tested. Three control oligonucleotides (R01002, R01014, Neg1) of different lengths (16, 17 and 18 nucleotides, respectively) with no sequence complementarity to any human or mouse mRNA were included as negative controls, and three ANGPTL4-specific oligonucleotides (A24047M (SEQ ID NO: 106), A24072M (SEQ ID NO: 129), A24095Mi (SEQ ID NO: 151)) with confirmed knockdown efficiency were used as positive controls. Mouse breast cancer cells (4T1 cells) were treated with each oligonucleotide at a single concentration of 5 μM. After 3 days, the cell supernatant was replaced with fresh medium containing 5 μM of each ASO and incubated for another 3 days. The cells were then lysed and mRNA levels were determined by QuantiGene RNA Singleplex assay. Hprt1 was used as a housekeeping gene for normalization of Angptl4 expression.

[0087] As shown in FIG. 17, 15 ASOs (A24146Mi (SEQ ID NO: 247), A24047M (SEQ ID NO: 106), A24126Mi (SEQ ID NO: 227), A24120Mi (SEQ ID NO: 221), A24104M (SEQ ID NO: 207), A24108M (SEQ ID NO: 211), A24110M (SEQ ID NO: 213), A24139Mi (SEQ ID NO: 240), A24103M (SEQ ID NO: 206), A24112M (SEQ ID NO: 217), A24139Mi (SEQ ID NO: 240), A24139Mi (SEQ ID NO: 241), A24139Mi (SEQ ID NO: 242), A24139Mi (SEQ ID NO: 243), A24139Mi (SEQ ID NO: 244), A24139Mi (SEQ ID NO: 245), A24139Mi (SEQ ID NO: 246), A24139Mi (SEQ ID NO: 247), A24139Mi (SEQ ID NO: 248), A24139Mi (SEQ ID NO: 249), A24139Mi (SEQ ID NO: 250), A24139Mi (SEQ ID NO: 251), A24139Mi (SEQ ID NO: 252), A24139Mi (SEQ ID NO: 253), A24139Mi (SEQ ID NO: 254), A24139Mi (SEQ ID NO: 255), A24139Mi (SEQ ID NO: 256), A24139Mi (S Row number 107), A24122HMe (sequence number 196), A24113M (sequence number 108), A24125Mi (sequence number 226), A24099M (sequence number 202), A24095Mi (sequence number 151)) reduced Angptl4 expression by more than 75% (corresponding to a residual Angptl4-mRNA expression of less than 0.25), while control oligonucleotides (Neg1, R01002, R01014) reduced Angptl4 mRNA expression by only less than 50% (corresponding to a residual Angptl4-mRNA expression of more than 0.5) (Figure 17).

[0088] Example 18: Second single-dose screening of mouse Angptl4-specific ASOs in Renca cells For further confirmation in different cell lines, the same treatment as in Example 17 was applied to mouse Renca cells. This resulted in the detection of 19 Angptl4-specific ASOs (A24143Mi (SEQ ID NO: 244), A24047M (SEQ ID NO: 106), A24095Mi (SEQ ID NO: 151), A24125Mi (SEQ ID NO: 226), A24110M (SEQ ID NO: 213), A24148Mi (SEQ ID NO: 151), A24120Mi (SEQ ID NO: 221), A24104M (SEQ ID NO: 207), A24109M (SEQ ID NO: 212), A24139Mi (SEQ ID NO: 240), A24103M (SEQ ID NO: 213), A24147Mi (SEQ ID NO: 213), A24149Mi (SEQ ID NO: 213), A24150Mi (SEQ ID NO: 213), A24151Mi (SEQ ID NO: 213), A24152Mi (SEQ ID NO: 213), A24153Mi (SEQ ID NO: 213), A24154Mi (SEQ ID NO: 213), A24155Mi (SEQ ID NO: 213), A24156Mi (SEQ ID NO: 213), A24157Mi (SEQ ID NO: 213), A24159Mi (SEQ ID NO: 213), A24158Mi (SEQ ID NO: 213), A24159Mi (SEQ ID NO: 213), A24159Mi (SEQ ID NO: 213), A24159Mi (SEQ ID NO: 21 06), A24122HMe (SEQ ID NO: 196), A24131Mi (SEQ ID NO: 232), A24138Mi (SEQ ID NO: 239), A24123Mi (SEQ ID NO: 224), A24146Mi (SEQ ID NO: 247), A24117Mi (SEQ ID NO: 218), A24130Mi (SEQ ID NO: 231), A24144Mi (SEQ ID NO: 245)) resulted in more than 75% Angptl4 knockdown (corresponding to a residual Angptl4-mRNA expression of less than 0.25) (Figure 18).

[0089] Example 19: IC of selected mouse ANGPTL4-specific antisense oligonucleotides 50 decision Based on the knockdown efficiency results in 4T1 and Renca cells (Figures 17, 18), nine ASOs with the strongest knockdown efficacy in Renca and 4T1 cells (A24103M (SEQ ID NO: 206), A24110M (SEQ ID NO: 213), A24122HMe (SEQ ID NO: 196), A24120Mi (SEQ ID NO: 221), A24125Mi (SEQ ID NO: 226), A24139Mi (SEQ ID NO: 240), A24143Mi (SEQ ID NO: 244), A24146Mi (SEQ ID NO: 247), A24148Mi (SEQ ID NO: 151)) were selected based on the half inhibitory concentration (IC 50 ) values ​​were selected for determination.

[0090] Primary mouse hepatocytes were treated with different concentrations of each ASO for 3 days. After 3 days, mRNA expression was analyzed using QuantiGene Singleplex RNA assay. From Figure 19 and Table 9, it can be seen that the selected Angptl4-specific ASOs suppressed Angptl4 mRNA expression with IC in the nanomolar range. 50 It is demonstrated that the inhibition is dose-dependent at high values.

[0091] Table 9 shows the IC of selected Angptl4-specific ASOs determined in primary human hepatocytes. 50 Indicates the value. * is R 2 <0.85; ASOs with increased potential to induce caspase 3 / 7 resulting in a dose-dependent decrease in Hprt1 levels: [Table 9]

[0092] Conclusions based on Examples 7-11 and 17-19: A series of 47 additional ASOs with specificity for human ANGPTL4 were tested to select several ASOs that robustly reduced human ANGPTL4 expression at the mRNA level in primary hepatocytes. Treatment with 16 of the tested ASOs demonstrated >70% knockdown of ANGPTL4 mRNA in primary human hepatocytes, thereby highlighting the IC of the most potent candidates. 50 Values ​​were in the low nanomolar range.

[0093] To perform in vivo experiments in mouse models, ASOs with specificity against mouse Angptl4 were designed, and successful candidate ASOs were selected for in vivo studies to robustly knockdown mouse Angptl4 expression in vitro.

[0094] Collectively, a comprehensive set of in vitro experiments identified a highly potent human ANGPTL4-specific ASO that is suitable for the development of ASO-based ANGPTL4-targeted therapeutics.

Claims

1. An ANGPTL4 inhibitor comprising an oligonucleotide comprising 12 to 22 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes to the nucleic acid sequence of ANGPTL4 (human) of SEQ ID NO: 1 within the range of positions 1264 to 1293 thereof, and comprises a sequence selected from the group consisting of SEQ ID NO: 186, SEQ ID NO: 187, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, and combinations thereof, wherein the oligonucleotide inhibits expression of ANGPTL4.

2. The inhibitor according to claim 1, wherein the oligonucleotide consists of 12 to 22 nucleotides.

3. The inhibitor according to claim 1 or 2, wherein the modified nucleotide is selected from the group consisting of bridged nucleic acids such as LNA, cET, ENA, 2'fluoro modified nucleotides, 2'O-methyl modified nucleotides, 2'O-methoxyethyl modified nucleotides and combinations thereof.

4. The oligonucleotide is * +G * +T * A * C * T * G * G * C * C * G * T * T * G * +A * +G * +G (SEQ ID NO: 186), +G*+A*+A*G*T*A*C*T*G*G*C*C*G*T*+T*+G*+A (SEQ ID NO: 187), +G * +G * +A * +G * C * G * G * A * A * G * T * A * C * T * G * +G * +C (SEQ ID NO: 42), +A * +T * +G * G * A * G * C * G * G * A * A * G * T * +A * +C * +T * +G (SEQ ID NO: 43), +G * +G * +A * T * G * G * A * G * C * G * G * A * A * G * +T * +A * +C (SEQ ID NO: 44), and combinations thereof, where + represents an LNA nucleotide; * The inhibitor according to any one of claims 1 to 3, wherein represents an internucleotide phosphorothioate (PTO) bond.

5. The inhibitor of any one of claims 1 to 4, wherein the inhibitor inhibits expression of ANGPTL4 at nanomolar or micromolar concentrations.

6. 6. A pharmaceutical composition comprising an inhibitor according to any one of claims 1 to 5 and a pharma- ceutically acceptable carrier, excipient, diluent, or combination thereof.

7. An inhibitor according to any one of claims 1 to 5 or a pharmaceutical composition according to claim 6 for use in a method for the prevention and / or treatment of a disorder involving an ANGPTL4 imbalance.

8. 8. The inhibitor or pharmaceutical composition according to claim 7, wherein the disorder is cardiometabolic disease, obesity, diabetes such as type 2 diabetes, hypercholesterolemia, hypertriglyceridemia (HTG), dyslipidemia, pancreatitis, metabolic syndrome, familial hyperchylomicronemia syndrome (FCS), influenza infection and / or cancer.

9. 9. The inhibitor or pharmaceutical composition according to claim 7 or 8, wherein the disorder is hypercholesterolemia, and the hypercholesterolemia is homozygous familial hypercholesterolemia (HoFH) or heterozygous familial hypercholesterolemia (HeFH).

10. The disorder is cancer, the cancer being selected from the group consisting of breast cancer, lung cancer, malignant melanoma, lymphoma, skin cancer, bone cancer, prostate cancer, liver cancer, brain cancer, cancer of the larynx, gallbladder, pancreas, testis, rectum, parathyroid gland, thyroid gland, adrenal gland, nervous tissue, head and neck, colon, stomach, bronchus, kidney, basal cell carcinoma, squamous cell carcinoma, metastatic skin cancer, osteosarcoma, Ewing's sarcoma, reticulum cell sarcoma, liposarcoma, myeloma, giant cell tumor, small cell lung tumor, islet cell tumor, primary brain tumor, meningioma, acute and chronic lymphocytic and granulocytic tumors, The inhibitor or pharmaceutical composition according to claim 7 or 8, which is selected from acute and chronic myeloid leukemia, hairy cell tumor, adenoma, hyperplasia, medullary carcinoma, intestinal ganglioneuroma, Wilms' tumor, seminoma, ovarian tumor, leiomyoma, cervical dysplasia, retinoblastoma, soft tissue sarcoma, malignant carcinoid, localized skin lesion, rhabdomyosarcoma, Kaposi's sarcoma, osteogenic sarcoma, malignant hypercalcemia, renal cell tumor, polycythemia vera, adenocarcinoma, anaplastic astrocytoma, glioblastoma multiforme, leukemia or epidermoid carcinoma.

11. 11. The inhibitor or pharmaceutical composition according to any one of claims 7 to 10, wherein the inhibitor or composition is suitable for local or systemic administration.

12. 12. The inhibitor or pharmaceutical composition according to any one of claims 7 to 11, wherein the composition is suitable for single or repeated administration.

Citation Information

Patent Citations

  • Compositions and methods of using angiopoietin-like 4 proteins

    JP2008507531A

  • Angiopoietin-like 4 protein inhibitors, combinations and their uses

    JP2008507536A

  • Monoclonal antibody against angiopoietin-like protein 4 (angptl4)

    JP2008526857A

  • Oligonucleotide modulators and their use in B-cell CLL / lymphoma 11A (BCL11A)

    JP2016520310A

  • Antiproliferative agent

    US20120207770A1